Abbvie Biotherapeutics Inc.

Jn Biosciences LLC

The University of Texas System

Protein Design Labs, Inc.

Pdl Biopharma, Inc.

Abbott Biotherapeutics Corp.

Gene Techno Science Co., Ltd.

Kaken Pharmaceutical Company, Ltd.

Abmuno Therapeutics LLC

Georgetown University

Facet Biotech Corporation

Livtech Inc. — Teikyo University Biotechnology Research Center

Iowa Immunotherapy Investigators

Abbview Biotherapeutics Inc.

Livtech, Inc.

J Yun Tso

Naoya Tsurushita

Shankar Kumar

Nicholas F Landolfi

Gao Liu

Marna Williams

Yong-Jun Liu

Kui Shin Voo

Laura Bover

David Powers

Taymar E Hartman

Ping Y Huang

Paul W Sauer

John E Burky

Mark C Wesson

Thomas J Robinson

Braeden D Partridge

Maximiliano Vasquez

Paul Robert Hinton

George J Weiner

Shigeyuki Kon

Omar Duramad

Michael S Cole

Roger Gingrich

Brian K Link

Koji Nakamura

Man Sung Co

Cary L Queen

Anton Wellstein

Toshimitsu Uede

Debra Chao

Tatsuhiro Harada

Rie Tajima

Yimin He

Claudio Anasetti

Sheri A Kostelny

Jennifer McPhate Green

Nicolas F Landolfi

Brian Link

Roger Dept Of Internal Medicine Gingrich

The invention provides bifunctional molecules including an antibody specifically binding to CD122 and an extracellular domain of CTLA-4. The bifunctional molecules specifically bind to CD122 and CTLA-4 ligands, CD80 and CD86 and inhibit their function in immune activation. The bifunctional molecules can inhibit interaction of CD122 with its ligands IL-2 and IL-15 and inhibit interaction of CD80 and CD86 with their counter-receptor, CD28. These bifunctional molecules can suppress Signals 2 and 3 of immune responses as a single therapeutic agent for treatment of immune disorders.

Bifunctional molecules for treatment of immune disorders

The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.

Antibodies to TIGIT

The invention provides bispecific antibodies having one arm binding to a cancer associated antigen on a cancer cell, such as CD33, EGFR or PD-L1, and a second arm binding to a costimulatory molecule, such as OX40, CD40, GITR, ICOS or 4-1BB. Bridging by the bispecific antibody between cancer cells expressing the cancer associated antigen and immune cells expressing the costimulatory molecule results in clustering of the costimulatory molecules and selective activation of the immune cells at a location proximate to the cancer cells. Thus, the immune cells can exert an immunotherapeutic effect against the cancer cells with reduced toxicity to healthy tissue.

Bispecific antibodies which bind PD-L1 and GITR

Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Anti-OX40 antibodies and methods of using the same

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Therapeutic use of anti-CS1 antibodies

The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C&#x3bc;3 and C&#x3bc;4 regions of a C&#x3bc; constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C&#x3bc; constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.

Hybrid constant regions

The present disclosure is directed to expression vectors, comprising a weakened SV40 promoter, and recombinant mammalian cells capable of producing high levels of a polypeptide of interest, methods of generating and using such recombinant mammalian cells.

Vectors and host cells comprising a modified SV40 promoter for protein expression

The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.

DAC HYP compositions

DAC HYP compositions and methods

The invention provides constant regions incorporating a cysteine mutation and linked to a &#x3bc; tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and &#x3bc; tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization.

Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece

Nucleic acid encoding anti-OX40 antibodies

Growing community of inventors

Menlo Park, CA, United States of America

J Yun Tso